News & Updates

Retinal Consultants of Arizona is Now Hiring Ophthalmic Technicians to Travel with our Amazing Physicians and Staff!

The ideal candidate will possess the following. Ophthalmology experience preferred, but willing to train the right candidate with Medical Assistant Experience. Medical Assistant must possess certification from an accredited program Must be able to work flexible hours and be able to travel via car or plane throughout the state. Photography (FA and OCT) experience helpful Must… Read More »


Dr. Sujit Itty Discusses Stem Cell Research for DRY AMD on Phoenix AZTV Morning Mix

Watch Dr. Sujit Itty of Retinal Consultants of Arizona discuss Stem Cell Research taking place at the Retinal Research Institute in Phoenix, AZ    Information For Patients With Geographic Atrophy Related To Dry Age-Related Macular Degeneration – An Experimental Treatment Of Severe Vision Loss From Advanced Dry Age-Related Macular Degeneration. What Is The Investigational… Read More »


EUROTIMES – Innovation in Retina Surgery – Dr. Pravin U. Dugel Interview

INNOVATION IN RETINA SURGERY: Technological innovation is crucial to the continued improvement 
of vitreoretinal surgery. Leigh Spielberg Posted: EUROTIMES – Thursday, March 1, 2018 Technological innovation is crucial to the continued improvement of vitreoretinal surgery. This was abundantly apparent during the RetinaTech Bio-Engineering Session during the 17th EURETINA Congress in Barcelona, Spain. Subtitled “Where Surgery… Read More »


Retinal Research Institute: Nation’s First FDA-Monitored Stem Cell Research Study for Advanced Dry Age-Related Macular Degeneration

Information for Patients with Geographic Atrophy Related to Dry Age-Related Macular Degeneration – An Experimental Treatment of Severe Vision Loss from Advanced Dry Age-Related Macular Degeneration. What is the Investigational treatment? This investigational treatment includes using an implant to replace some of the cells in the retina that have been lost or damaged due to… Read More »


Dr. Pravin U. Dugel – Modern Retina from Ophthalmology Times

These novel strategies may change DME treatment paradigm By: Michelle Dalton, ELS; Reviewed by Pravin U. Dugel, MD There is no denying that the anti-vascular endothelial growth factor A (anti-VEGF-A) monotherapy has “absolutely revolutionized our treatment of diabetic macular edema (DME).” However, there is a subset of patients in whom the anti-VEGFs are not an… Read More »



Orbis International Welcomes New Members to its Board of Directors

Orbis welcomes Dr. Pravin Dugel, managing partner, Retinal Consultants of Arizona, and David Gitlin, President, UTC Aerospace Systems, to its Board of Directors. Pravin has been involved with Orbis since 2010 as a member of our Volunteer Faculty, specializing in retinal diseases including diabetic retinopathy. “I am extremely honored to join the Orbis Board of… Read More »


Dr. Pravin Dugel – Highlights from Day 1 of Retina Subspecialty Day 2017Findings from neovascular AMD studies a highlight from Day 1

Findings from neovascular AMD studies a highlight from Day 1 NEW ORLEANS – The 48-week results of the HAWK and HARRIER studies on brolucizumab (Novartis) for the treatment of neovascular age-related macular degeneration (AMD) were one of the highlights from Day 1 at Retina Subspecialty Day. Pravin Dugel, MD, (Phoenix, Ariz.) first described the antibody… Read More »


Novartis’ eye drug clearly works, but edging out Eylea won’t be easy – Dr. Pravin U. Dugel

Dive Brief: Novartis AG’s investigational eye drug bested Regeneron Pharmaceutical Inc.’s Eylea on additional secondary endpoints of two late-stage studies, bolstering the treatment’s potential to go head to head with Regeneron’s market leader. In HAWK trial, 35% fewer patients had intra-retinal fluid (IRF) and/or sub-retinal fluid (SRF) after 16 weeks of taking Novartis’ brolucizumab 6 mg versus… Read More »


Novartis’ VEGF inhibitor demonstrates clinically relevant anatomic, visual gains – Dr. Pravin Dugel

MEETING NEWS American Academy of Ophthalmology Meeting NEW ORLEANS — Novartis’ first-in-kind molecule brolucizumab achieved clinically relevant anatomic and visual acuity gains in patients with age-related macular degeneration with every-12-week dosing, according to a speaker. Two dosages of the single-chain antibody fragment VEGF inhibitor were compared with Eylea (aflibercept, Regeneron) in two phase 3 trials,… Read More »